A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multi-Center Study of Weight-Reducing Effect and Safety in Obese Patients With Untreated Dyslipidemias.
Phase of Trial: Phase III
Latest Information Update: 12 May 2009
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms RIO-Lipids
- Sponsors Sanofi-Synthelabo
- 12 May 2009 Additional locations Australia, Canada, Finland, Spain, Sweden, Switzerland identified as reported by ClinicalTrials.gov.
- 12 May 2009 Actual patient number (1033) added as reported by ClinicalTrials.gov.
- 14 Sep 2006 New trial record.